ArticleESMO open2025

Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022.

H C Puhr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.